Why did Poly Medicure (POLYMED) stock move recently?

On 8/4/2026, Poly Medicure moved +3.4% — No specific company catalyst or news was reported for August 4; the stock rose with broader market or sector momentum ahead of the scheduled August 7 board meeting for quarterly results. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Poly Medicure (POLYMED) overvalued or fairly valued?

MarketChacha shows Poly Medicure's valuation in context — a forward P/E of about 38.9, a price-to-book of about 6.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Poly Medicure's revenue?

Poly Medicure reported revenue of ₹1,662 Cr for FY2026, with net profit of ₹336 Cr, per official filings.

What is the share price of Poly Medicure (POLYMED)?

Poly Medicure last traded at ₹1,863.90 (+5.2% on the day), as of 8/11/2026 — a delayed quote shown for education, not investment advice.

Poly Medicure

POLYMED · NSE · Healthcare · India

Snapshot

TickerPOLYMED

ExchangeNSE

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryIndia

HeadquartersNew Delhi, India

Websitewww.polymedicure.com

Filings tracked3

About Poly Medicure

Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, such as I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid lines over the wire, extension line, enteral connector, central venous catheters, and huber needle; dialysis and renal care products, comprising peritoneal dialysis set, haemocent, standard and safety fistula needle, dialyzer, bloodlines and dialysis system. It also provides cardiology products PTFE wire, inflation device, Y-connector, manifold, introducer, IV Cannula, hydrophilic wire, guiding catheter, drug eluting stent, PTCA dilation catheter, diagnostic catheter, and electrocardiograph electrodes; vaccular access products; oncology products; diagnostics products, such as blood collection tubes, safety blood collection set, blood collection needles, and standard needle holder. In addition, the company offers transfusion system products, including blood bags, blood administration set, and others; anesthesia and respiratory care products, comprising variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, aerosol therapy masks, ventilator circuits, suction catheters, spinal needle, polyciser, oxygen catheter, nebulizer compressor system, twin bore nasal oxygen cannula mucus extractor, HME filter, oro-pharyngeal airways, endotracheal tubes, catheter mount, and brain circuit; urology products, including urine collection bags, leg bag set, irrigation sets, foley balloon and urine drainage catheters, and urine collection bags with measured volume meters; wound drainage; and gastroenterology products. The company was incorporated in 1995 and is based in New Delhi, India.

Who owns it

Promoters65.1%
Institutions18.1%
Public & other16.8%

58 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend16.1% → 20.2%

Margin has expanded by about 4.1 points — the business is getting more profitable.

Growth qualityrev 14% · PAT 23%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (BSE (official results filing)). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹632 Cr · EPS 11.50

Est. earnings growth +53.8%

Next fiscal year

Rev ₹2,763 Cr · EPS 47.03

Est. earnings growth +22.6%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: BSE (official results filing)

Annual

Quarterly · last 6

Revenue (FY2026)

₹1,662 Cr

Net margin

20.2%

Revenue CAGR (3y)

+14.2%

Profit CAGR (3y)

+23.3%

EPS (FY2026)

33.15

Net profit (FY2026)

₹336 Cr

Ask MarketChacha about POLYMED

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 4, 2026
No specific company catalyst or news was reported for August 4; the stock rose with broader market or sector momentum ahead of the scheduled August 7 board meeting for quarterly results.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	₹1,662 Cr	₹336 Cr	33.15	20.2%
FY2025	₹1,670 Cr	₹339 Cr	—	20.3%
FY2024	₹1,376 Cr	₹258 Cr	—	18.8%
FY2023	₹1,115 Cr	₹179 Cr	—	16.1%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	₹431 Cr	₹88 Cr	8.69	20.4%
2026Q2	₹525 Cr	—	—	—
2026Q1	₹443 Cr	₹81 Cr	7.95	18.2%
2025Q4	₹419 Cr	₹78 Cr	7.73	18.7%
2025Q3	₹444 Cr	₹92 Cr	—	20.7%
2025Q2	₹403 Cr	₹93 Cr	—	23.1%

Figures as reported, in ₹ (crore). Source: BSE (official results filing).

Filings & announcements

2026

Statement Of Deviation & Variation For The Quarter Ended 30Th June, 2026
enclosed
BSE8/10/2026
Monitoring Agency Report
The company submitted the Monitoring Agency Report for the Quarter ended 30th June, 2026.
BSE8/10/2026
Investor Presentation
ENCLOSED
BSE8/7/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.